News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by MacroGenics, Inc.
MacroGenics to Participate in Upcoming Investor Conference
June 11, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
May 13, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
May 03, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
April 03, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
March 01, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
February 27, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conference
February 02, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conference
January 08, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
November 02, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
October 31, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
September 05, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
August 31, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
July 31, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
May 04, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
April 24, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
March 22, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
March 08, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
March 07, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
March 02, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium
February 13, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
February 06, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors
January 04, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
November 17, 2022
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics to Participate in Upcoming Investor Conferences
November 02, 2022
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call
October 26, 2022
From
MacroGenics, Inc.
Via
GlobeNewswire
Tickers
MGNX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close